4D Molecular Therapeutics, Inc. (FDMT) has been beaten down lately with too much selling pressure. While the stock has lost 26% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier. How to Determine if a Stock is Oversold We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a mo ...

EMERYVILLE, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced a poster presentation at the 2024 North American Cystic Fibrosis Conference (NACFC) in Boston, Massachusetts on September 26-28, 2024. 2024 NACFC Poster Presentation Details: Title: Transgene expression and CFTR channel function in hu ...

4D Molecular Therapeutics, Inc. (FDMT) closed the last trading session at $15.62, gaining 6.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $50.78 indicates a 225.1% upside potential. The mean estimate comprises nine short-term price targets with a standard deviation of $17.77. While the lowest estimate of $36 indicates a 130.5% increase from the current price level, the most op ...

A downtrend has been apparent in 4D Molecular Therapeutics, Inc. (FDMT) lately with too much selling pressure. The stock has declined 21.9% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround. Here is How to Spot Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technic ...

EMERYVILLE, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in a fireside chat at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. Members of the management team will also be available for one-on-one meetings. H.C. Wainwright 4th Annual Ophthalmo ...

4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $0.77 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 12.50%. A quarter ago, it was expected that this company would post a loss of $0.73 per share when it actually produced a loss of $0.66, delivering a surprise of 9.59%. Over the last four quarters, the com ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 | --- | --- | |---------------------------------------------------------------------------------------------|-------------- ...

Exhibit 99.1 4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights • Announced positive interim results from the Population Extension cohort of the Phase 2 PRISM clinical trial for 4D-150 in a broad wet age-related macular degeneration (wet AMD) population, which includes patients representative of the planned Phase 3 study population, affirming favorable safety profile and robust clinical activity • Strengthened senior leadership team and announced formation of a world class Ophthal ...

Dhaval Desai, PharmD, named as Chief Development Officer; will oversee late-stage Product Development, Medical Affairs, Scientific Communications, Regulatory and Quality operations; most recently SVP & Chief Development Officer at Iveric Bio where he led development and approval of IZERVAY Christopher Simms named as Chief Commercial Officer, effective September 25, 2024; will oversee Precommercial and Commercial organizations, pre-launch preparations and development; most recently SVP & Chief Commercial Off ...

LOS ANGELES, July 22, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D Molecular Therapeutics" or "the Company") (NASDAQ: FDMT) for violations of the securities laws. If you are a shareholder who suffered a loss, click here to participate. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder r ...